Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,183 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01949818 | Treatment of Diffuse Large B Cell Lymphoma | unknown | Phase 4 | 120 | Mingzhi ZhangOTHER | 1 | Dec 30, 2015 | clinicaltrials |
| NCT00594126 | Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma | completed | Phase 1 | 20 | Geron CorporationINDUSTRY | 1 | Dec 24, 2015 | clinicaltrials |
| NCT00718601 |
| Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma |
| completed |
| Phase 1 |
| 40 |
| Geron CorporationINDUSTRY |
| 1 |
| Dec 24, 2015 |
| clinicaltrials |
| NCT00575965 | Simvastatin in Waldenstrom's Macroglobulinemia | terminated | Phase 2 | 18 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 16, 2015 | clinicaltrials |
| NCT01010568 | Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL) | terminated | Phase 2 | 10 | Georgetown UniversityOTHER | 1 | Dec 15, 2015 | clinicaltrials |
| NCT02438501 | Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular Lymphoma(WUCC-NHL02) | unknown | Phase 3 | 166 | Di DengOTHER | 1 | Dec 14, 2015 | clinicaltrials |
| NCT02449252 | Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Follicular Lymphoma | unknown | Phase 3 | 120 | Wuhan UniversityOTHER | 1 | Dec 14, 2015 | clinicaltrials |
| NCT02449265 | Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma | unknown | Phase 3 | 160 | Wuhan UniversityOTHER | 1 | Dec 14, 2015 | clinicaltrials |
| NCT02449278 | The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma | unknown | Phase 3 | 120 | Wuhan UniversityOTHER | 1 | Dec 14, 2015 | clinicaltrials |
| NCT01793844 | A Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma Patients | unknown | — | 732 | Sun Yat-sen UniversityOTHER | 1 | Dec 11, 2015 | clinicaltrials |
| NCT02569996 | A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma | completed | Phase 3 | 124 | Hoffmann-La RocheINDUSTRY | 1 | Dec 10, 2015 | clinicaltrials |
| NCT00023764 | Bortezomib in Treating Patients With Lymphoproliferative Disorders | completed | Phase 2 | 103 | National Cancer Institute (NCI)NIH | 1 | Dec 8, 2015 | clinicaltrials |
| NCT02109861 | Microdose Study of Melphalan, Bortezomib and Dexamethasone(Phase-0-MM) | unknown | Early Phase 1 | 6 | Henrik GregersenOTHER | 1 | Dec 8, 2015 | clinicaltrials |
| NCT02624440 | Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Newly Diagnosed Multiple Myeloma(SUTRICA) | unknown | Phase 2 | 300 | Henrik GregersenOTHER | 1 | Dec 8, 2015 | clinicaltrials |
| NCT00514371 | A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma(TIME-2) | completed | Phase 2 / Phase 3 | 22 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 7, 2015 | clinicaltrials |
| NCT00538187 | Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma | terminated | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT00588094 | Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL | completed | Phase 2 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 4, 2015 | clinicaltrials |
| NCT00693433 | Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT00799539 | A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients | no longer available | — | — | Janssen-Ortho Inc., CanadaINDUSTRY | 1 | Dec 2, 2015 | clinicaltrials |
| NCT01624701 | Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells | terminated | Phase 1 / Phase 2 | 3 | Singapore General HospitalOTHER | 1 | Nov 30, 2015 | clinicaltrials |
| NCT01045928 | Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 | 5 | Case Comprehensive Cancer CenterOTHER | 1 | Nov 26, 2015 | clinicaltrials |
| NCT00083551 | UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy | completed | Phase 3 | 668 | University of ArkansasOTHER | 1 | Nov 23, 2015 | clinicaltrials |
| NCT01746030 | Geriatric Assessments in Senior Adults With Multiple Myeloma | completed | — | 42 | Washington University School of MedicineOTHER | 1 | Nov 20, 2015 | clinicaltrials |
| NCT01135849 | B-Receptor Signaling in Cardiomyopathy | completed | — | 99 | Daniel BernsteinOTHER | 1 | Nov 17, 2015 | clinicaltrials |
| NCT01691300 | C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT(ACTMM) | completed | N/A | 30 | Chang Gung Memorial HospitalOTHER | 1 | Nov 13, 2015 | clinicaltrials |
| NCT00002850 | Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy | completed | Phase 3 | 212 | Gary MorrowOTHER | 3 | Nov 11, 2015 | clinicaltrials |
| NCT01076556 | Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | Phase 1 | 9 | National Cancer Institute (NCI)NIH | 1 | Nov 11, 2015 | clinicaltrials |
| NCT01126502 | Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia | terminated | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Nov 4, 2015 | clinicaltrials |
| NCT00924040 | Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Oct 29, 2015 | clinicaltrials |
| NCT00578045 | UARK 2006-28 Human Cord Blood Transplantation in Advanced Hematological Malignancies | withdrawn | Phase 1 | 0 | University of ArkansasOTHER | 1 | Oct 26, 2015 | clinicaltrials |
| NCT00999414 | UARK 2009-32 Compassionate Use Study of Carfilzomib(2009-32) | no longer available | — | — | University of ArkansasOTHER | 1 | Oct 26, 2015 | clinicaltrials |
| NCT00103506 | Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma | completed | Phase 3 | 646 | Janssen Research & Development, LLCINDUSTRY | 17 | Oct 19, 2015 | clinicaltrials |
| NCT01621672 | UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma | completed | Phase 3 | 42 | University of ArkansasOTHER | 1 | Oct 19, 2015 | clinicaltrials |
| NCT00276536 | Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma(IFNa) | completed | Phase 1 | 35 | The Cleveland ClinicOTHER | 1 | Oct 14, 2015 | clinicaltrials |
| NCT01263418 | Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas | withdrawn | Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 0 | Oct 12, 2015 | clinicaltrials |
| NCT01485835 | A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 | 8 | Emory UniversityOTHER | 1 | Oct 12, 2015 | clinicaltrials |
| NCT00111748 | UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients | completed | Phase 3 | 180 | University of ArkansasOTHER | 1 | Oct 6, 2015 | clinicaltrials |
| NCT01521533 | NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma | completed | Phase 2 | 28 | TME Pharma AGINDUSTRY | 4 | Oct 6, 2015 | clinicaltrials |
| NCT02461290 | Rituximab Therapy in Follicular Lymphoma in Combination With Chemotherapy - REFLECT 1 | completed | — | 99 | Hoffmann-La RocheINDUSTRY | 1 | Sep 30, 2015 | clinicaltrials |
| NCT01735604 | Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy | unknown | Phase 1 / Phase 2 | 50 | Chinese PLA General HospitalOTHER | 1 | Sep 29, 2015 | clinicaltrials |
| NCT01180569 | Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | Sep 25, 2015 | clinicaltrials |
| NCT00609869 | Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab | completed | Phase 2 | 29 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 17, 2015 | clinicaltrials |
| NCT01084837 | Study of Induction Treatment With Velcade and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal Failure(RENVEL) | completed | Phase 2 | 60 | PETHEMA FoundationOTHER | 1 | Sep 17, 2015 | clinicaltrials |
| NCT00057564 | A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma | completed | Phase 3 | 470 | Celgene CorporationINDUSTRY | 16 | Sep 11, 2015 | clinicaltrials |
| NCT02541643 | Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma | no longer available | — | — | Sundar JagannathOTHER | 1 | Sep 4, 2015 | clinicaltrials |
| NCT00131937 | Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2015 | clinicaltrials |
| NCT00915408 | A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma(CRD) | completed | Phase 1 / Phase 2 | 32 | King's College Hospital NHS TrustOTHER | 1 | Sep 2, 2015 | clinicaltrials |
| NCT01236391 | Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)(PCYC-1104-CA) | completed | Phase 2 | 115 | Pharmacyclics LLC.INDUSTRY | 4 | Aug 28, 2015 | clinicaltrials |
Data updated 24 days agoSource updated Dec 30, 2015source: clinicaltrials